Table 5.

Tabulated overall survival values for two human cohorts, as well as pembrolizumab patient sorted into higher or lower predicted OS using predictive model.

Overall Survival of Pembrolizumab Patients (months)	Median
High Predicted OS	35.57
Low Predicted OS	6.98
Log-Rank	p = 0.026
Overall Survival of Human Cohorts (months)	Median
Nivolumab	10.27
Pembrolizumab	14.27
Log-Rank	p = 0.057

While OS differences were not significant on log-rank test between two cohorts overall, the difference between groups sorted by predictive model was statistically significant.